International Verapamil SR/Trandolapril [INVEST] Genes Study

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.

C. Pepine, E. Handberg, R. Cooper-DeHoff, et al.. (2003). JAMA. Cited 1,213 times. https://doi.org/10.1001/JAMA.290.21.2805

Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension.

C. Pepine, E. Handberg-Thurmond, R. Marks, et al.. (1998). Journal of the American College of Cardiology. Cited 141 times. https://doi.org/10.1016/S0735-1097(98)00423-9

β‐Adrenergic Receptor Gene Polymorphisms and β‐Blocker Treatment Outcomes in Hypertension

MA Pacanowski, Y. Gong, R. Cooper‐DeHoff, et al.. (2008). Clinical Pharmacology & Therapeutics. Cited 130 times. https://doi.org/10.1038/clpt.2008.139

Genetic Variation in PEAR1 Is Associated With Platelet Aggregation and Cardiovascular Outcomes

J. Lewis, K. Ryan, J. O’Connell, et al.. (2013). Circulation: Cardiovascular Genetics. Cited 101 times. https://doi.org/10.1161/CIRCGENETICS.111.964627

Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics

C. McDonough, S. E. Burbage, Julio D. Duarte, et al.. (2013). Journal of Hypertension. Cited 73 times. https://doi.org/10.1097/HJH.0b013e32835e2a71

KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST)

A. Beitelshees, Y. Gong, Danxin Wang, et al.. (2007). Pharmacogenetics and Genomics. Cited 73 times. https://doi.org/10.1097/FPC.0b013e32810f2e3c

Cholesteryl Ester Transfer Protein (CETP) Polymorphisms Affect mRNA Splicing, HDL Levels, and Sex-Dependent Cardiovascular Risk

A. Papp, J. Pinsonneault, Danxin Wang, et al.. (2012). PLoS ONE. Cited 72 times. https://doi.org/10.1371/journal.pone.0031930

CACNA1C Gene Polymorphisms, Cardiovascular Disease Outcomes, and Treatment Response

A. Beitelshees, Hrishikesh Navare, Danxin Wang, et al.. (2009). Circulation: Cardiovascular Genetics. Cited 71 times. https://doi.org/10.1161/CIRCGENETICS.109.857839

Association of CYP3A5 Polymorphisms with Hypertension and Antihypertensive Response to Verapamil

T. Langaee, Y. Gong, H. Yarandi, et al.. (2007). Clinical Pharmacology & Therapeutics. Cited 65 times. https://doi.org/10.1038/sj.clpt.6100090

G protein receptor kinase 4 polymorphisms: &bgr;-Blocker Pharmacogenetics and treatment-related outcomes in Hypertension

A. Vandell, M. Lobmeyer, Brian E. Gawronski, et al.. (2012). Hypertension. Cited 64 times. https://doi.org/10.1161/HYPERTENSIONAHA.112.198721

Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES).

T. Gerhard, Y. Gong, A. Beitelshees, et al.. (2008). American heart journal. Cited 53 times. https://doi.org/10.1016/j.ahj.2008.03.007

Genetic Variation in the &bgr;2 Subunit of the Voltage-Gated Calcium Channel and Pharmacogenetic Association With Adverse Cardiovascular Outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES)

Yuxin Niu, Y. Gong, T. Langaee, et al.. (2010). Circulation: Cardiovascular Genetics. Cited 42 times. https://doi.org/10.1161/CIRCGENETICS.110.957654

Promoter Polymorphisms in ACE (Angiotensin I–Converting Enzyme) Associated With Clinical Outcomes in Hypertension

Andrew D. Johnson, Yan Gong, Danxin Wang, et al.. (2009). Clinical Pharmacology & Therapeutics. Cited 42 times. https://doi.org/10.1038/clpt.2008.194

Large‐Scale Gene‐Centric Analysis Identifies Polymorphisms for Resistant Hypertension

V. Fontana, C. McDonough, Y. Gong, et al.. (2014). Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease. Cited 39 times. https://doi.org/10.1161/JAHA.114.001398

Pharmacogenomic Association of Nonsynonymous SNPs in SIGLEC12, A1BG, and the Selectin Region and Cardiovascular Outcomes

C. McDonough, Y. Gong, S. Padmanabhan, et al.. (2013). Hypertension. Cited 34 times. https://doi.org/10.1161/HYPERTENSIONAHA.111.00823

Chromosome 9p21 Haplotypes and Prognosis in White and Black Patients With Coronary Artery Disease

Y. Gong, A. Beitelshees, R. Cooper-DeHoff, et al.. (2011). Circulation: Cardiovascular Genetics. Cited 32 times. https://doi.org/10.1161/CIRCGENETICS.110.959296

Aromatase Gene Polymorphisms Are Associated with Survival among Patients with Cardiovascular Disease in a Sex-Specific Manner

A. Beitelshees, Julie A. Johnson, Megan L. Hames, et al.. (2010). PLoS ONE. Cited 26 times. https://doi.org/10.1371/journal.pone.0015180

Genome-wide association analysis of common genetic variants of resistant hypertension

Nihal El Rouby, C. McDonough, Y. Gong, et al.. (2018). The Pharmacogenomics Journal. Cited 23 times. https://doi.org/10.1038/s41397-018-0049-x

Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment

JH Karnes, C. McDonough, Y. Gong, et al.. (2012). The Pharmacogenomics Journal. Cited 20 times. https://doi.org/10.1038/tpj.2012.34

Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β‐Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil‐SR Trandolapril Study) Trials

O. Magvanjav, Y. Gong, C. McDonough, et al.. (2017). Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease. Cited 16 times. https://doi.org/10.1161/JAHA.117.006522

Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes

J. Karnes, Y. Gong, M. Pacanowski, et al.. (2013). Pharmacogenetics and Genomics. Cited 15 times. https://doi.org/10.1097/FPC.0000000000000012

CES1P1 variant −816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril

Hao‐Jie Zhu, T. Langaee, Y. Gong, et al.. (2016). European Journal of Clinical Pharmacology. Cited 14 times. https://doi.org/10.1007/s00228-016-2029-x

β2‐Adrenergic Receptor Gene Affects the Heart Rate Response of β‐Blockers: Evidence From 3 Clinical Studies

Mohamed H. Shahin, N. Rouby, D. Conrado, et al.. (2019). The Journal of Clinical Pharmacology. Cited 9 times. https://doi.org/10.1002/jcph.1443

Lack of association of the HMGA1 IVS5-13insC variant with type 2 diabetes in an ethnically diverse hypertensive case control cohort

J. Karnes, T. Langaee, C. McDonough, et al.. (2013). Journal of Translational Medicine. Cited 5 times. https://doi.org/10.1186/1479-5876-11-12